RxDoctor Payments Data

Vanessa Andrada

Physician Assistant · Live Oak, TXNPI 1942071238

Payments from drug & device makers

$703in general payments, 2019–2025

Across 41 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$415
  • Novo Nordisk$100
  • Si-bone, Inc.$58
  • Exact Sciences$55
  • Lilly USA, LLC$41
  • AstraZeneca$20
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$703100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie27$415
Novo Nordisk5$100
Si-bone, Inc.2$58
Exact Sciences3$55
Lilly USA, LLC2$41
AstraZeneca1$20
Pfizer1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$703 in reported general payments places this provider in the 55th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$55,999
Medicare patients
110
Services billed
1,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$47,537
FarxigaDapagliflozin Propanediol33$40,839
MounjaroTirzepatide14$17,353
TrulicityDulaglutide11$11,899
Rosuvastatin Calcium102$1,566
Atorvastatin Calcium99$1,157
Albuterol Sulfate HfaAlbuterol Sulfate28$843
Nifedipine ErNifedipine25$709
Sertraline Hcl18$644
Losartan Potassium75$630
Ezetimibe28$557
Diclofenac Sodium12$556
Omeprazole33$552
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide19$542
Gabapentin32$518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$100$47,53730 claims
AstraZenecaFarxiga$20$40,83933 claims
Lilly USA, LLCMounjaro, Trulicity$41$29,25225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Live Oak

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →